Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com

StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report published on Friday. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a buy rating and set a $7.00 target price on shares of Aptose Biosciences in a report on Friday, June 14th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $9.00.

Aptose Biosciences Stock Performance

Shares of APTO stock opened at $0.37 on Friday. Aptose Biosciences has a fifty-two week low of $0.33 and a fifty-two week high of $3.32. The firm has a market cap of $6.74 million, a P/E ratio of -0.06 and a beta of 1.26. The business’s 50 day moving average price is $0.43 and its 200-day moving average price is $0.84.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.15. As a group, equities analysts predict that Aptose Biosciences will post -2.62 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC acquired a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences as of its most recent filing with the Securities & Exchange Commission. 26.62% of the stock is owned by hedge funds and other institutional investors.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.